natgillin/translations-raw huggingface dataset:
Flixabi fortyndes dog med natriumchlorid 9 mg/ml (0,9%) infusionsvæske, opløsning. 
Flixabi is however, diluted in sodium chloride 9 mg/ml (0.9%) solution for infusion.
I uge 30 var andelen af personer med klinisk remission højere i 8-ugers gruppen (59,6 %; 31/52) end i 12-ugers gruppen (35,3 %, 18/51; p = 0,013). 
At week 30, the proportion of subjects in clinical remission was higher in the q8 week (59.6%, 31/52) than the q12 week maintenance treatment group (35.3%, 18/51; p=0.013).
5.2, men der kan ikke gives nogen anbefalinger vedrørende dosering hos børn under 6 år. 
Currently available pharmacokinetic data are described in section 5.2 but no recommendation on a posology can be made in children younger than 6 years.
Infunder ikke Flixabi i den samme intravenøse slange med andre midler. 
Do not infuse Flixabi concomitantly in the same intravenous line with other agents.
Komplet fistula respons (%)b a A ≥ 50 % reduktion fra baseline i antallet af drænede fistulaer over en periode på ≥ 4 uger. 
b a A ≥ 50% reduction from baseline in the number of draining fistulas over a period of ≥ 4 weeks b Absence of any draining fistulas
Rekonstituer under aseptiske forhold hvert Flixabi-hætteglas med 10 ml vand til injektionvæsker ved hjælp af en sprøjte med en gauge 21 (0,8 mm) kanyle eller en mindre kanyle. 
Under aseptic conditions, reconstitute each Flixabi vial with 10 ml of water for injections, using a syringe equipped with a 21-gauge (0.8 mm) or smaller needle.
Hvis disse lægemidler ikke virker godt nok, vil du få Flixabi til behandling af din sygdom. 
If these medicines do not work well enough, you will be given Flixabi to treat your disease.
Under behandling med Flixabi 
During treatment with Flixabi
Procent forsøgspersoner i klinisk respons og i vedvarende klinisk respons Klinisk respons i uge 8a 
Percentage of subjects in clinical response and in sustained clinical response Clinical response at week 8
Ikke almindelig: Kramper, neuropati. 
Seizure, neuropathy.
Gennembrudsinfektion efter vaccination (efter eksponering for infliximab i uterus)* Benigne, maligne og uspecificerede tumorer (inkl. 
Vaccine breakthrough infection (after in utero exposure to infliximab) Neoplasms benign, malignant and unspecified (including cysts and polyps) Rare:
Procent forsøgspersoner i klinisk remission og vedvarende remission Klinisk remission i uge 8a 
Percentage of subjects in clinical remission and sustained remission Clinical remission at week 8
Infliximab Vedligeholdelse (5 mg/kg) (n = 96) 
Infliximab Maintenance (5 mg/kg) (n=96)
• Infektioner, som skyldes et nedsat immunforsvar 
• Infections due to a weakened immune system
Infliximab + AZA Kombinationsterap i 
Infliximab + AZA Combination therapy
Tabel 5 Effekter på respons og remissionshastighed, data fra ACCENT I (uge-2 responderende) ACCENT I (uge-2 responderende) % patienter 
Table 5 Effects on response and remission rate, data from ACCENT I (week-2 responders)
• Behandle aktiv Crohns sygdom 
• Treat active Crohn's disease,
Placebovedligeholdelse (n = 110) 
Placebo Maintenance (n=110)
• Du må kun få Flixabi under graviditeten, hvis lægen finder det nødvendigt. 
Flixabi should only be used during pregnancy if your doctor feels it is necessary for you.
Du har en højere risiko, hvis du er 65 år eller derover. 
If you are 65 or older,
Tegn på lungeproblemer såsom hoste, åndedrætsbesvær eller trykken for brystet Tegn på et problem i nervesystemet (inklusive øjenproblemer) såsom tegn på slagtilfælde (pludselig følelsesløshed eller svaghed i ansigt, arme eller ben, særligt i den ene side af kroppen; pludselig forvirring, besvær med at tale eller forstå; besvær med at se med det ene eller begge øjne, gangbesvær, svimmelhed, tab af balance- eller koordinationsevne eller svær hovedpine), krampeanfald, prikken/følelsesløshed et sted i kroppen, eller svaghed i arme eller ben, ændringer i synet såsom dobbeltsyn eller andre øjenproblemer. 
• Signs of a nervous system problem (including eye problems) such as signs of a stroke (sudden numbness or weakness of your face, arm or leg, especially on one side of your body; sudden confusion, trouble speaking or understanding; trouble seeing in one or both eyes, trouble walking, dizziness, loss of balance or coordination or a severe headache), fits, tingling/numbness in any part of your body, or weakness in arms or legs, changes in eyesight such as double vision or other eye problems
I det andet kliniske studie (ASSERT) blev 279 patienter randomiseret til behandling med enten placebo (gruppe 1, n = 78) eller 5 mg/kg infliximab (gruppe 2, n = 201) i uge 0, 2 og 6 og derefter hver 6. uge indtil uge 24. 
In the second clinical study (ASSERT), 279 patients were randomised to receive either placebo (Group 1, n=78) or 5 mg/kg infliximab (Group 2, n=201) at 0, 2 and 6 weeks and every 6 weeks to week 24.
Bulløst udslæt, seborre, rosacea, hudpapilom, hyperkeratose, unormal hudpigmentering. 
Bullous eruption, seborrhoea, rosacea, skin papilloma, hyperkeratosis, abnormal skin pigmentation.
Fortynd det samlede volumen af den rekonstituerede dosis Flixabi-opløsning til 250 ml med natriumchlorid 9 mg/ml (0,9 %) infusionsvæske, opløsning. 
Dilute the total volume of the reconstituted Flixabi solution dose to 250 ml with sodium chloride 9 mg/ml (0.9%) solution for infusion.
Dit barn bør ikke få levende vacciner som BCG indenfor 6 måneder efter fødslen. 
Live vaccines such as BCG should not be given to your baby within 6 months after birth.
Induktionsbehandling af moderat til svært aktiv Crohns sygdom Effekten af en enkeltdosisbehandling med infliximab blev vurderet hos 108 patienter med aktiv Crohns sygdom (Crohn's Disease Activity Index (CDAI) ≥ 220 ≤ 400) i et randomiseret, dobbeltblind, 
Induction treatment in moderately to severely active Crohn's disease The efficacy of a single dose treatment with infliximab was assessed in 108 patients with active Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥ 220 ≤ 400) in a randomised, double-blinded, placebocontrolled, dose-response study.
Meget almindelig: Abdominalsmerter, kvalme. 
Abdominal pain, nausea.
Klinisk respons i uge 30a 
Clinical response at week 30
En større andel patienter i den kombinerede infliximab-behandlingsgruppe var i stand til at afbryde kortikosteroider og stadig blive i klinisk remission sammenlignet med placebobehandlingsgruppen i både uge 30 (22,3 % mod 7,2 %, p < 0,001, samlede ACT 1- & ACT 2-data) og uge 54 (21,0 % mod 8,9 %, p = 0,022, ACT 1-data). 
A greater proportion of patients in the combined infliximab treatment group were able to discontinue corticosteroids while remaining in clinical remission compared to the placebo treatment group at both week 30 (22.3% vs. 7.2%, p < 0.001, pooled ACT 1 & ACT 2 data) and week 54 (21.0% vs. 8.9%, p=0.022, ACT 1 data).
Før behandling med Flixabi 
Before treatment with Flixabi
Hypotension, hypertension, ekkymose, hedeture, blussen. 
Hypotension, hypertension, ecchymosis, hot flush, flushing.
• Øvrige indholdsstoffer: saccharose, polysorbat 80, monobasisk natriumphosphatmonohydrat og dibasisk natriumphosphatheptahydrat. 
• The other ingredients are sucrose, polysorbate 80, monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate.
Uge 30 
Week 30
Infliximabs sikkerhed og virkning hos børn under 6 år med Crohns sygdom er ikke undersøgt. 
The safety and efficacy of infliximab have not been studied in children with Crohn's disease below the age of 6 years.
• Flere børn end voksne, der får Flixabi, fik infektioner. 
• More children taking Flixabi developed infections as compared to adults.
I begge studier var patienterne randomiseret til at få enten placebo, 5 mg/kg infliximab eller 10 mg/kg infliximab i uge 0, 2, 6, 14 og 22, og i ACT 1 i uge 30, 38 og 46. 
In both studies, patients were randomised to receive either placebo, 5 mg/kg infliximab, or 10 mg/kg infliximab at weeks 0, 2, 6, 14 and 22, and in ACT 1 at weeks 30, 38 and 46.
Tegn på leverproblemer (inklusive hepatitis B-infektion, hvis du tidligere har haft hepatitis B) såsom gulfarvning af hud eller øjne, mørkebrun urin, smerter eller hævelser i øvre højre side af maven, ledsmerter, hududslæt eller feber 
• Signs of a liver problem (including hepatitis B infection when you have had hepatitis B in the past) such as yellowing of the skin or eyes, dark-brown coloured urine, pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever
Otteogtres procent (21/31) af patienter behandlet med infliximab, der fik et 5 mg/kg doseringsregimen, opnåede en klinisk effekt mod 26 % (8/31) af placebobehandlede patienter (p = 0,002). 
Sixty eight percent (21/31) of infliximab-treated patients receiving a 5 mg/kg dose regimen achieved a clinical response vs. 26% (8/31) placebo-treated patients (p=0.002).
Seponering af Flixabi-behandling bør overvejes hos patienter, hvor signifikante blodanormaliteter er bekræftet. 
Discontinuation of Flixabi therapy should be considered in patients with confirmed significant haematologic abnormalities.
Crohns sygdom er en betændelsessygdom i tarmen. 
Crohn's disease Crohn's disease is an inflammatory disease of the bowel.
• Andre hudproblemer såsom erythema multiforme, lichenoide reaktioner (kløende, rødligt-lilla hududslæt og/eller trådlignende gråhvide linjer på slimhinderne), blærer og afskalning af huden eller bylder (furunkulose) 
• Other skin problems such as erythema multiforme, lichenoid reactions (itchy reddish-purple skin rash and/or threadlike white-grey lines on mucous membranes), blisters and peeling skin, or boils
Efter markedsføring er der rapporteret tilfælde af forværret hjerteinsufficiens hos infliximabpatienter, med eller uden identificerbare prædisponerende faktorer. 
There have been post-marketing reports of worsening heart failure, with and without identifiable precipitating factors, in patients taking infliximab.
Flixabi er indiceret til behandling af moderat til svær plaque psoriasis hos voksne patienter, som ikke responderede på, eller som har en kontraindikation for eller som ikke tåler anden systemisk behandling inklusive ciclosporin, methotrexat eller psoralen ultraviolet A (PUVA) (se pkt. 
Flixabi is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen ultra-violet A (PUVA) (see section 5.1).
Hjerteinsufficiens (debuterende eller forværret), arytmi, besvimelse, bradykardi. 
Cardiac failure (new onset or worsening), arrhythmia, syncope, bradycardia.
• En sjælden blodkræft, som hovedsageligt rammer teenagedrenge eller unge mænd 
• A rare blood cancer affecting mostly teenage boys or young men (hepatosplenic T-cell lymphoma)
• Du skal have de anbefalede vaccinationer, før du starter behandling med Flixabi. 
• You should receive recommended vaccinations before starting Flixabi treatment.
En risiko for udvikling af hepatosplenisk T-celle-lymfom hos patienter, der bliver behandlet med Flixabi, kan ikke udelukkes (se pkt. 
A risk for the development for hepatosplenic T-cell lymphoma in patients treated with Flixabi cannot be excluded (see section 4.8).
Hvis du er i tvivl, så kontakt lægen, før du får Flixabi. 
If you are not sure, talk to your doctor before you are given Flixabi.
• Hævelse af lever (hepatitis) eller galdeblæren, leverskade 
• Swelling of the liver (hepatitis) or gall bladder, liver damage
I det første studie (P01522), som havde en dobbeltblind fase på 3 måneder, modtog 70 patienter enten 5 mg/kg infliximab eller placebo i uge 0, 2, 6 (35 patienter i hver gruppe). 
In the first study (P01522), which had a 3 month double-blind phase, 70 patients received either 5 mg/kg infliximab or placebo at weeks 0, 2, 6 (35 patients in each group).
• Små røde eller lilla pletter, der skyldes blødning under huden • Unormale værdier for et protein i blodet kaldet ‘komplementfaktor', som er en del af immunsystemet. 
• Abnormal values of a blood protein called ‘complement factor' which is part of the immune system.
Flixabi administreres intravenøst. 
Flixabi should be administered intravenously.
Efter markedsføring er hændelser af anafylaktisk lignende reaktioner, inklusive strube/spiserørs ødemer og alvorlige bronkospasmer, og kramper blevet forbundet med administrering af infliximab (se pkt. 
In post-marketing experience, cases of anaphylactic-like reactions, including laryngeal/pharyngeal oedema and severe bronchospasm, and seizure have been associated with infliximab administration (see section 4.4).
Tuberkulose, bakterieinfektioner, inklusive sepsis og pneumoni, invasive svampeinfektioner, virale infektioner og andre opportunistiske infektioner har været observeret hos patienter, der fik infliximab. 
Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other opportunistic infections have been observed in patients receiving infliximab.
I et toksicitetsstudie vedrørende udvikling udført på mus med et analogt antistof, som selektivt hæmmer den funktionelle aktivitet af muse- TNFα, var der ingen tegn på maternal toksicitet, embryotoksicitet eller teratogenicitet (se pkt. 
In a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNFα, there was no indication of maternal toxicity, embryotoxicity or teratogenicity (see section 5.3).
Neutropeni, leukopeni, anæmi, lymfadenopati. 
Neutropenia, leucopenia, anaemia, lymphadenopathy.
Infliximabvedligeholdelse 5 mg/kg (n = 113) (p-værdi) 
Infliximab Maintenance 5 mg/kg (n=113) (p value)
Under overvågning efter markedsføring er der rapporteret tilfælde af gulsot og hepatitis, nogle med tegn på autoimmun hepatitis, hos patienter, der fik infliximab (se pkt. 
In post-marketing surveillance, cases of jaundice and hepatitis, some with features of autoimmune hepatitis, have been reported in patients receiving infliximab (see section 4.4).
Fortynd ikke det rekonstituerede Flixabi-koncentrat med andre infusionsvæsker. 
Do not dilute the reconstituted Flixabi solution with any other diluent.
• Hudproblemer såsom blæredannelse, vorter, unormal hudfarve eller pigmentering, eller hævede læber, eller fortykkelse af huden eller rød, skællende hud og afskalning af huden 
• Skin problems such as blistering, warts, abnormal skin colouration or pigmentation, or swollen lips, or thickening of the skin, or red, scaly and flaky skin
De patienter, som af investigator blev vurderet til at have et klinisk respons i uge 10, blev randomiseret og fik 5 mg/kg infliximab enten hver 8. eller hver 12. uge som et vedligeholdelsesbehandlingsregimen. 
Patients assessed by the investigator to be in clinical response at week 10 were randomised and received 5 mg/kg infliximab at either q8 weeks or q12 weeks as a maintenance treatment regimen.
Klinisk responsa Klinisk remission 
Clinical Remission
(p < 0,001)* * P-værdier repræsenterer hver infliximab-behandlingsgruppe vs. AZA monoterapi. 
* P-values represent each infliximab treatment group vs. AZA monotherapy
Infliximabvedligeholdelse 10 mg/kg (n = 112) (p-værdi) 
Infliximab Maintenance 10 mg/kg (n=112) (p value)
Unormal leverfunktion, forhøjede leveraminotransferaser. 
Hepatic function abnormal, transaminases increased.
Der er rapporteret om enkelte tilfælde af aktiv tuberkulose under og efter behandling for latent tuberkulose hos patienter i behandling med Flixabi. 
Some cases of active tuberculosis have been reported in patients treated with Flixabi during and after treatment for latent tuberculosis.
• Lungehindebetændelse, der giver skarpe smerter, som forværres ved vejrtrækning (pleuritis) 
• Inflamed lining of the lung, causing sharp chest pains that feel worse with breathing (pleurisy)
Infliximabs sikkerhed og virkning hos børn og unge under 18 år for indikationen juvenil reumatoid arthritis er ikke klarlagt. 
The safety and efficacy of infliximab in children and adolescents younger than 18 years for the indication of juvenile rheumatoid arthritis have not been established.
Spontane alvorlige bivirkninger hos børn efter markedsføring af infliximab inkluderer maligniteter inklusive hepatosplenisk T-celle-lymfom, forbigående leverenzymabnormaliteter, lupus lignende syndromer og positive autoantistoffer (se pkt. 
Post-marketing spontaneous serious adverse reactions with infliximab in the paediatric population have included malignancies including hepatosplenic T-cell lymphomas, transient hepatic enzyme abnormalities, lupus-like syndromes, and positive auto-antibodies (see sections 4.4 and 4.8).
• Tegn på en sygdom i immunsystemet såsom ledsmerter, udslæt på kinderne eller arme, som er følsomme over for solen (lupus) eller hoste, åndenød, feber eller hududslæt (sarkoidose) 
• Signs of an immune system disorder such as joint pain or a rash on cheeks or arms that is sensitive to the sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis)
De mest almindeligt rapporterede infektioner var øvre luftvejsinfektioner og faryngitis. 
The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess.
Andelen af patienter med slimhindeheling i uge 26 var signifikant større i grupperne, der fik infliximab plus AZA (43,9 %; p < 0,001) eller infliximab-monoterapi (30,1 %; p = 0,023) sammenlignet med AZAmonoterapigruppen (16,5 %). 
The proportions of patients with mucosal healing at week 26 were significantly greater in the infliximab plus AZA combination (43.9%, p < 0.001) and infliximab monotherapy groups (30.1%, p=0.023) compared to the AZA monotherapy group (16.5%).
Antallet af hospitalsindlæggelser relateret til colitis ulcerosa var signifikant lavere i 5 og 10 mg/kg infliximab-behandlingsgrupperne end i placebogruppen (gennemsnitligt antal hospitalsindlæggelser per 100 forsøgsperson-år: 21 og 19 versus 40 i placebogruppen; hhv. p = 0,019 og p = 0,007). 
The number of ulcerative colitis-related hospitalisations was significantly lower in the 5 and 10 mg/kg infliximab treatment groups than in the placebo group (mean number of hospitalisations per 100 subject-years: 21 and 19 vs. 40 in the placebo group; p=0.019 and p=0.007, respectively).
Infliximabs sikkerhed og virkning hos børn og unge under 18 år for indikationen psoriasis er ikke klarlagt. 
The safety and efficacy of infliximab in children and adolescents younger than 18 years for the indication of psoriasis have not been established.
Der er set tilfælde af kortvarigt synstab under infusion eller inden for 2 timer efter infusion af infliximab. 
Cases of transient visual loss occurring during or within 2 hours of infliximab infusion have been reported.
Hvis du er i tvivl, om noget af ovenstående passer på dig, skal du kontakte lægen eller apotekspersonalet, før du får Flixabi. 
If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Flixabi.
Der blev observeret alvorlige infektioner og neutropeni i kliniske studier ved samtidig anvendelse af anakinra og et andet TNFα -blokerende middel, etanercept, uden nogen øget klinisk fordel sammenlignet med etanercept indgivet alene. 
Concurrent administration of TNF-alpha inhibitor and anakinra Serious infections and neutropenia were seen in clinical studies with concurrent use of anakinra and another TNFα-blocking agent, etanercept, with no added clinical benefit compared to etanercept alone.
• Fortæl din læge, før du får Flixabi, hvis du har en infektion, også selvom det er en meget let infektion. 
Infections • Tell your doctor before you are given Flixabi if you have an infection even if it is a very minor one.
Antallet af kirurgiske indgreb relateret til colitis ulcerosa var også lavere i 5 og 10 mg/kg infliximab-behandlingsgrupperne end i placebogruppen (gennemsnitligt antal kirurgiske indgreb per 100 forsøgsperson-år: 22 og 19 versus 34; hhv. p = 0,145 og p = 0,022). 
The number of ulcerative colitis-related surgical procedures was also lower in the 5 and 10 mg/kg infliximab treatment groups than in the placebo group (mean number of surgical procedures per 100 subject-years: 22 and 19 vs. 34; p=0.145 and p=0.022, respectively).
• Tegn på hjerteproblemer såsom ubehag i brystkassen eller brystsmerter, armsmerter, mavesmerter, åndenød, angst, ørhed, svimmelhed, besvimelse, svedtendens, kvalme, (utilpashed) opkastning, flakkende hjerte eller trykken i brystet, et hurtigt eller langsomt hjerteslag og hævelse af dine fødder. 
• Signs of a heart problem such as chest discomfort or pain, arm pain, stomach pain, shortness of breath, anxiety, lightheadedness, dizziness, fainting, sweating, nausea (feeling sick), vomiting, fluttering or pounding in your chest, a fast or a slow heartbeat, and swelling of your feet.
Hos patienter, som fik infliximab, er langt de fleste tilfælde forekommet hos patienter med Crohns sygdom eller colitis ulcerosa og de fleste blev rapporteret hos unge eller unge voksne mænd. 
The vast majority of infliximab cases have occurred in patients with Crohn's disease or ulcerative colitis and most were reported in adolescent or young adult males.
Graviditet, amning og frugtbarhed 
Pregnancy and breast-feeding, and fertility
• Tegn på infektion (inklusive tuberkulose (TB)) såsom feber, træthedsfølelse, hoste, der kan være vedvarende, åndenød, influenzalignende symptomer, vægttab, natlig svedtendens, diarré, sår, ansamling af pus i tarmen eller omkring anus (absces), tandproblemer eller brændende smerte, når du lader vandet 
• Signs of infection (including TB) such as fever, feeling tired, cough which may be persistent, shortness of breath, flu-like symptoms, weight loss, night sweats, diarrhoea, wounds, collection of pus in the gut or around the anus (abscess), dental problems or burning sensation when urinating
Hjælpestoffer: Saccharose, polysorbat 80, monobasisk natriumphosphatmonohydrat og dibasisk natriumphosphatheptahydrat. 
Excipients: sucrose, polysorbate 80, monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate.
Debuterende eller forværring af allerede eksisterende psoriasis, inklusive pustuløs psoriasis (primært palmoplantaris), urticaria, udslæt, pruritus, øget svedtendens, tør hud, svampedermatitis, eksem, alopeci. 
New onset or worsening psoriasis including pustular psoriasis (primarily palm & soles), urticaria, rash, pruritus, hyperhidrosis,
Klinisk remission og slimhindeheling forekom i en større andel af patienterne i den kombinerede infliximabbehandlingsgruppe sammenlignet med placebobehandlingsgruppen i uge 54 (henholdsvis 34,6 % mod 16,5 %, p < 0,001 og 46,1 % mod 18,2 %, p < 0,001). 
Clinical remission and mucosal healing occurred in a greater proportion of patients in the combined infliximab treatment group compared to the placebo treatment group at week 54 (34.6% vs. 16.5%, p < 0.001 and 46.1% vs. 18.2%, p < 0.001, respectively).
Der er rapporteret om melanom og Merkelcellekarcinom hos patienter, der har fået TNF-blokerende behandling, herunder infliximab (se pkt. 
Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy, including infliximab (see section 4.8).
Fortæl straks din læge, hvis du får nye eller forværrede tegn på hjertesvigt under behandlingen med Flixabi. 
Tell your doctor straight away if you get new or worsening signs of heart failure during treatment with Flixabi.
Perifer iskæmi, tromboflebitis, hæmatom. 
Peripheral ischaemia, thrombophlebitis, haematoma.
Opløsningen må ikke anvendes, hvis det indeholder uigennemsigtige partikler, er misfarvet eller indeholder andre fremmedlegemer. 
Do not use if opaque particles, discolouration, or other foreign particles are present.
Ved uge 8 blev 45 patienter randomiseret og fik 5 mg/kg infliximab enten hver 8. eller hver 12. uge som et vedligholdelsesregimen. 
At week 8, 45 patients were randomised and received 5 mg/kg infliximab at either q8 weeks or q12 weeks as a maintenance treatment regimen.
Det skal du vide, før du begynder at bruge Flixabi Sådan skal du bruge Flixabi Bivirkninger 
What Flixabi is and what it is used for What you need to know before you use Flixabi How Flixabi will be given Possible side effects
Du må ikke få Flixabi og Orencia samtidig. 
Flixabi and Orencia should not be used together.